Philippe Truffinet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philippe Truffinet has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Karthinathan Thangavelu
Département de biostatistique, Sanofi, Cambridge, MA, États-Unis
5 shared publications- Aaron E. Miller
Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 shared publications - Myriam Benamor
Sanofi, 1 Avenue Pierre Brossolette, Chilly-Mazarin 91385, France
3 shared publications Pascal Rufi
Sanofi Genzyme Cambridge MA United States
3 shared publicationsAnnie Purvis
Sanofi, Cambridge, MA 02142, USA
2 shared publications- Jerome de Seze
Department of Neurology and Clinical Investigation Center, Strasbourg University Hospital, Strasbourg, France
2 shared publications
Latest Publications
- Open Access
- 22 February 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 109, 107090
Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab
- 22 February 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 109, 107090
Open AccessPsychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab
- Open Access
- 9 September 2024
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (6) , 1607-1625
Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis
Introduction Lymphocyte depletion via anti-CD52 monoclonal antibody (mAb) therapy is an effective treatment strategy for relapsing–remitting multiple sclerosis (MS) but is associated with infusion/injection-associated reactions (IARs) and autoimmune-related adverse events (AEs). Gatralimab is a next-generation humanized anti-CD52 mAb. Methods Two first-in-human trials were conducted in participants with progressive MS to assess the pharmacodynamics, pharmacokinetics, and safety of gatralimab administered via subcutaneous (SC) and intravenous (IV) routes, and to determine the effect of different comedication regimes on IARs to SC gatralimab. A Phase 1 trial (NCT02282826) included double-blind, placebo-controlled sequential ascending single IV (1, 3.5, and 12 mg) and SC (12, 36, and 60 mg) dose groups. A Phase 1b trial (NCT02977533) involved five groups who received SC gatralimab (36, 48, or 60 mg) and different comedications. A long-term safety (LTS) study (NCT02313285) examined safety and pharmacodynamics over 4 years. Results Gatralimab produced depletion of lymphocytes (dose-dependently) and CD4+ regulatory T cells, with partial repopulation to normal values by approximately 12 months. Peak serum gatralimab concentrations followed dose-proportionality and were delayed by 6.0–7.5 days following SC administration. Treatment-emergent AEs, including IARs, were reported for most participants but were generally of mild or moderate severity, and treatment-emergent serious AEs were mostly MS-related. Methylprednisolone and antihistamine comedications were associated with reduced incidence of fevers and skin and subcutaneous tissue AEs, respectively. During the LTS study, one participant (3.0%) experienced an autoimmune-related AE (Basedow’s disease), and subsequently died from pulmonary sepsis deemed unrelated to gatralimab by the investigator. Conclusions These data show that gatralimab achieves the desired pharmacodynamic effect of lymphocyte depletion followed by repopulation, and has an acceptable safety profile, including low risk of non-MS autoimmunity. Although gatralimab is no longer in development for MS, insights from these trials may inform the development of comedication regimes of future anti-CD52 mAbs and subcutaneous formulations of other lymphocyte-depleting mAbs. Trial registration NCT02282826, NCT02977533, NCT02313285.
- 9 September 2024
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (6) , 1607-1625
Open AccessPhase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis
Introduction Lymphocyte depletion via anti-CD52 monoclonal antibody (mAb) therapy is an effective treatment strategy for relapsing–remitting multiple sclerosis (MS) but is associated with infusion/injection-associated reactions (IARs) and autoimmune-related adverse events (AEs). Gatralimab is a next-generation humanized anti-CD52 mAb. Methods Two first-in-human trials were conducted in participants with progressive MS to assess the pharmacodynamics, pharmacokinetics, and safety of gatralimab administered via subcutaneous (SC) and intravenous (IV) routes, and to determine the effect of different comedication regimes on IARs to SC gatralimab. A Phase 1 trial (NCT02282826) included double-blind, placebo-controlled sequential ascending single IV (1, 3.5, and 12 mg) and SC (12, 36, and 60 mg) dose groups. A Phase 1b trial (NCT02977533) involved five groups who received SC gatralimab (36, 48, or 60 mg) and different comedications. A long-term safety (LTS) study (NCT02313285) examined safety and pharmacodynamics over 4 years. Results Gatralimab produced depletion of lymphocytes (dose-dependently) and CD4+ regulatory T cells, with partial repopulation to normal values by approximately 12 months. Peak serum gatralimab concentrations followed dose-proportionality and were delayed by 6.0–7.5 days following SC administration. Treatment-emergent AEs, including IARs, were reported for most participants but were generally of mild or moderate severity, and treatment-emergent serious AEs were mostly MS-related. Methylprednisolone and antihistamine comedications were associated with reduced incidence of fevers and skin and subcutaneous tissue AEs, respectively. During the LTS study, one participant (3.0%) experienced an autoimmune-related AE (Basedow’s disease), and subsequently died from pulmonary sepsis deemed unrelated to gatralimab by the investigator. Conclusions These data show that gatralimab achieves the desired pharmacodynamic effect of lymphocyte depletion followed by repopulation, and has an acceptable safety profile, including low risk of non-MS autoimmunity. Although gatralimab is no longer in development for MS, insights from these trials may inform the development of comedication regimes of future anti-CD52 mAbs and subcutaneous formulations of other lymphocyte-depleting mAbs. Trial registration NCT02282826, NCT02977533, NCT02313285.
- Open Access
- 1 August 2020
- Published by Elsevier in Reproductive Toxicology
- Vol. 95, 45-50
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide
- 1 August 2020
- Published by Elsevier in Reproductive Toxicology
- Vol. 95, 45-50
Open AccessPregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide
- 26 March 2019
- Published by Elsevier in Revue Neurologique
- Vol. 175, S93
Données des grossesses chez les patientes atteintes de SEP traitées par tériflunomide : études cliniques et données post-commercialisation
- 26 March 2019
- Published by Elsevier in Revue Neurologique
- Vol. 175, S93
Données des grossesses chez les patientes atteintes de SEP traitées par tériflunomide : études cliniques et données post-commercialisation
- Open Access
- 1 January 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 59, 229-231
Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study
- 1 January 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 59, 229-231
Open AccessEfficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study
- 8 May 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (5) , e1.22-e1
Efficacy and safety of teriflunomide in chinese patients with relapsing forms of ms: a subgroup analysis of the phase 3 tower study
Objectives TOWER (NCT00751881), a phase 3 study in patients with relapsing forms of MS (RMS), was conducted in 26 countries, including 32 sites in China. In the overall population, teriflunomide 14 mg significantly reduced annualised relapse rate (ARR; 36.3%, p=0.0001) and risk of disability worsening confirmed for ≥12 weeks (12 w-CDW) by 31.5% vs placebo (p=0.0442). The objective of this analysis was to report efficacy and safety outcomes in Chinese patients enrolled in TOWER. Methods Patients with RMS were randomised 1:1:1 to placebo, teriflunomide 7 mg or 14 mg for ≥48 weeks. The primary and key secondary endpoints were ARR and 12 w-CDW, respectively. Incidence of adverse events (AEs) was monitored throughout the study. Results Of 1165 patients randomised and treated in TOWER, 148 (12.7%) were Chinese patients from Chinese sites. Demographic and baseline disease characteristics of this population were comparable to the overall TOWER population, with the exception that Chinese patients had a shorter time since first symptoms of MS (mean (SD): 5.02 (5.25) years vs overall, 8.0 (6.72) years), and a smaller proportion had received another disease-modifying therapy within the last 2 years (2.0% vs 32.8% overall). Within the Chinese population, teriflunomide 14 mg reduced ARR and risk of 12 w-CDW by 71.2% (p=0.0012) and 68.1% (p=0.1194) vs placebo, respectively. Incidence of AEs was consistent with the overall population. Two deaths (placebo, respiratory infection; 14 mg, suicide) were not considered related to study treatment. Conclusions In Chinese patients enrolled in TOWER, teriflunomide 14 mg reduced ARR and risk of 12 w-CDW vs placebo; the small number of patients in this subgroup may have contributed to the lack of statistical significance observed for 12 w-CDW. However, there was a consistency of outcomes between the Chinese subpopulation and the overall TOWER population in terms of efficacy and safety. Study supported by Sanofi Genzyme.
- 8 May 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (5) , e1.22-e1
Efficacy and safety of teriflunomide in chinese patients with relapsing forms of ms: a subgroup analysis of the phase 3 tower study
Objectives TOWER (NCT00751881), a phase 3 study in patients with relapsing forms of MS (RMS), was conducted in 26 countries, including 32 sites in China. In the overall population, teriflunomide 14 mg significantly reduced annualised relapse rate (ARR; 36.3%, p=0.0001) and risk of disability worsening confirmed for ≥12 weeks (12 w-CDW) by 31.5% vs placebo (p=0.0442). The objective of this analysis was to report efficacy and safety outcomes in Chinese patients enrolled in TOWER. Methods Patients with RMS were randomised 1:1:1 to placebo, teriflunomide 7 mg or 14 mg for ≥48 weeks. The primary and key secondary endpoints were ARR and 12 w-CDW, respectively. Incidence of adverse events (AEs) was monitored throughout the study. Results Of 1165 patients randomised and treated in TOWER, 148 (12.7%) were Chinese patients from Chinese sites. Demographic and baseline disease characteristics of this population were comparable to the overall TOWER population, with the exception that Chinese patients had a shorter time since first symptoms of MS (mean (SD): 5.02 (5.25) years vs overall, 8.0 (6.72) years), and a smaller proportion had received another disease-modifying therapy within the last 2 years (2.0% vs 32.8% overall). Within the Chinese population, teriflunomide 14 mg reduced ARR and risk of 12 w-CDW by 71.2% (p=0.0012) and 68.1% (p=0.1194) vs placebo, respectively. Incidence of AEs was consistent with the overall population. Two deaths (placebo, respiratory infection; 14 mg, suicide) were not considered related to study treatment. Conclusions In Chinese patients enrolled in TOWER, teriflunomide 14 mg reduced ARR and risk of 12 w-CDW vs placebo; the small number of patients in this subgroup may have contributed to the lack of statistical significance observed for 12 w-CDW. However, there was a consistency of outcomes between the Chinese subpopulation and the overall TOWER population in terms of efficacy and safety. Study supported by Sanofi Genzyme.
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data (S33.008)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data (S33.008)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Early vs Delayed Treatment with Teriflunomide 14 mg Results in Reduced Risk of Disability Progression in Patients with MS (P3.021)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Early vs Delayed Treatment with Teriflunomide 14 mg Results in Reduced Risk of Disability Progression in Patients with MS (P3.021)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Predicting Treatment Response to Teriflunomide in the TEMSO Study Using the Modified Rio Score (P2.108)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Predicting Treatment Response to Teriflunomide in the TEMSO Study Using the Modified Rio Score (P2.108)